FILTER

FILTERED INTERVIEW RESULTS

United States

Pharma & Life Sciences

Scott Bluestein

CEO & CIO, HERCULES CAPITAL

Hercules Capital explains why it is well positioned to benefit from a thriving life sciences and technology scene.

United States

Pharma & Life Sciences

James Sapirstein

PRESIDENT & CEO, AZURRX BIOPHARMA

AzurRx Biopharma has benefitted from the availability of financing to expand its pipeline.

United States

Pharma & Life Sciences

William H. Lewis

CHAIR & CEO, INSMED

2020 has been a transformative year for Insmed that is now undertaking three exciting programs for rare and serious diseases.

United States

Pharma & Life Sciences

Christiana Bardon

PORTFOLIO MANAGER, BURRAGE CAPITAL, MANAGING DIRECTOR, ONCOLOGY IMPACT FUND, MPM CAPITAL

Burrage Capital speaks to GBR about the current wave of enthusiasm investors are showing towards biotech.

United States

Pharma & Life Sciences

Jay A. Roberts

PRESIDENT & CEO, CANCER GENETICS, INC.

Cancer Genetics has merged with StemoniX and is addressing the challenges of drug discovery using innovative, science-based technologies and a highly-developed focus on the regulatory community.

United States

Pharma & Life Sciences

Kendalle O’Connell

PRESIDENT AND COO, MASSBIO

MassBio explains how it intends to ensure that Massachusetts remains a global leader for life sciences.

United States

Pharma & Life Sciences

Daphne Zohar & Bharatt Chowrira

FOUNDER AND CEO & PRESIDENT AND CHIEF OF BUSINESS AND STRATEGY, PURETECH HEALTH

PureTech Health is expanding swiftly with 24 product candidates that it has invented or initiated, 13 of which are in clinical testing, and two have received FDA clearance.